Current prospective management of patients with osteonecrosis drug-induced (bisphosphonates) of the jaws: our experience by Giudice, M & Cristofaro, M G
MEETING ABSTRACT Open Access
Current prospective management of patients
with osteonecrosis drug-induced
(bisphosphonates) of the jaws: our experience
M Giudice
*, M G Cristofaro
From de Senectute: Age and Health Forum
Catanzaro, Italy. 5-7 December 2009
Background
Bisphosphonates (BP) are frequently used for the treat-
ment of multiple myeloma, bone metastasis and for
osteoporosis, the most used are Alendronic and Zolen-
dronic acids (1). This type of drugs, especially Zolendro-
nic acid, pointed out a serious side effect: ostenecrosis
of the jaws (ONJ). It is demonstrated they reduce bone
turn-over and induce apoptosis of the osteoclasts. BP
have remarkable ability of anti-angiogenesis, that
together to micro-traumas and inflammations, it can be
a contributory cause of the ONJ onset.
Patients can remain asymptomatic even for a long
time, but secondary infection of the bone exposed due
to teeth extraction or other surgical procedures cause
pain (2), soft tissue swelling, purulent collections that
can drain in the mouth or outside.
Materials and methods
In Department of Maxillo-Facial Surgery, from January
2003 to September 2009, it has been observed 84
patients with ONJ. 56 are included in our screening pro-
gram: 50 patients were treated for cancer with acid
Zolendronic, 6 for osteoporosis with Alendronic acid;
the ONJ location was in the 24 pz (43%) the upper jaw,
in 30 (54%) the mandible, in 2 (3 %) both. ONJ devel-
oped in 31 pz (54%) after tooth extraction, in 15 (28%)
due to dental prosthesis micro-traumas, in 10 (18%) it
was spontaneous. Following the AAOMFS classification
(Table 1), 5 patients (8,9%) were in stage Ia, 2 (3,6%) in
stage Ib, 22 (39,3%) in stage IIa, 4 (7,2%) in stage IIb, 12
(21,4%) in stage IIIa, 11 (19,6%) were IIIb.
Results
The results are indicated in Table 2: in 10 patients the
results aren’t satisfactory; 26 show clinical condition
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Table 1 (AAOMFS)
Stage 0 (sub-clinic stage)
Stage I (bone-exposure without pain and infection)
a lesion < 1cm
b lesion > 1cm
Stage II (bone-exposure with pain and infection)
a lesion < 2cm
b lesion > 3cm
Stage III
a bone-exposure > 3cm with clear osteolyses
b pathological fractures; ect.
In stage I treatment was performed with clorexidina 0,2%, in stage II or III
antibiotic-therapy and clorexidina, in stage IIIb surgical therapy. In 18 pz we
have associate PiezoSurgery system, which exploits the ultrasounds action,
effective on the bone but absolutely atraumatic on the soft tissue.
Table 2
Patients Number Initial Stage Final stage
*3 *Ia *Ia
*10 *IIa *IIa
*4 *IIIa *IIIa
*9 *IIIb *IIIb
# 2 #Ia #IIa
#6 #IIa #IIb
# 2 #IIb #IIIa
^5 ^IIa ^Ib
^2 ^IIb ^Ib
^8 ^IIIa ^IIb
^ 2 ^IIIb ^IIb
+2 +Ib +0
+1 +IIa +0
*n. 26 clinical condition stationary
#n. 10 worsted
^n. 17 improved
+n. 3 clinically free from disease
Giudice and Cristofaro BMC Geriatrics 2010, 10(Suppl 1):A60
http://www.biomedcentral.com/1471-2318/10/S1/A60
© 2010 Giudice and Cristofaro; licensee BioMed Central Ltd.stationary (Figure 1); 17 are improved (Figure 2); 3 are
completely recovered (Figure 3) .
Conclusions
To date management of ONJ patients is difficult for the
prognosis and therapy, expecially for several cases.
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Figure 1 stage IIIa; after 6 months of treatment the clinical condition are stationary (antibiotic-therapy + PiezoSurgery system)
Figure 2 stage IIIa to IIa, the clinical condition are improved after 8 months of Treatment (antibiotic-therapy + PiezoSurgery system)
Figure 3 stage IIa to 0, clinical free from desease after ten months of treatment (antibiotic-therapy + PiezoSurgery system)
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